Conclusions
In this study we demonstrated that the PTP4A3 phosphatase could be a new
therapeutic target for COVID-19-related ARDS. We conclude that the novel
inhibitor KVX-053, also known as JMS-053, exhibits potential to become
an effective drug for the treatment of ARDS.